Vol. 5 No. 2 (2017): August 2017

Published: 2017-08-31

Editorial

Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial

Christian Marth

3-4
- PDF

Review

Metastatic soft tissue sarcomas: update on new agents and clinical studies

Attila Kollár, Bernd Kasper

5-11
- PDF
Nivolumab in renal cancer

Sabrina Rossetti, Sabrina Chiara Cecere, Carmela Pisano, Gelsomina Iovane, Jole Ventriglia, Imma Paciolla, Marilena Di Napoli

12-17
- PDF

Pro & Cons editorial

The role of laparoscopy in evaluating cytoreduction in advanced ovarian cancer

Anna Fagotti, Giovanni Scambia, Sandro Pignata, Carmela Pisano, Domenica Lorusso

18-21
- PDF

Breaking from the Lab

Immunotherapy in tumors failing check-point inhibitors:the sarcoma example – What we missed and where we are heading

Alessandra Merlini, Francesco Tolomeo, Sara Miano, Lorenzo D’Ambrosio, Dario Sangiolo, Giovanni Grignani

22-32
- PDF

Clinical original article

Anorectal function and quality of life after chemoradiotherapy in patients with anal canal carcinoma

Francesca De Felice, Daniela Musio, Gloria Bernardi, Lavinia Grapulin, Alessio Impagnatiello, Roberto Lisi, Cosima Maria Moschella, Marileda Indinnimeo, Vincenzo Tombolini

33-38
- PDF

Meet the expert

Case 1 – Stage IV low-grade serous ovarian carcinoma management in an elderly patient

Luisa Sánchez-Lorenzo, Antonio González-Martín, David M. Gershenson

39-45
- PDF
Case 2 – A case of secondary platinum-resistant ovarian cancer

Marilena Di Napoli, Domenica Lorusso

46-50
- PDF

Methodological corner

Patient-reported outcomes in ovarian cancer

Ilaria Sabatucci, Francesco Perrone

51-54
- PDF

Correspondence

Letter to the Editor

Sandro Pignata

55
- PDF